The Fight Just Born-Neonatal Cancer: Rare Occurrence with a Favorable Outcome but Challenging Management.
cancer
cancer predisposition syndrome
children
newborn
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
29 Apr 2022
29 Apr 2022
Historique:
received:
29
03
2022
revised:
21
04
2022
accepted:
27
04
2022
entrez:
14
5
2022
pubmed:
15
5
2022
medline:
15
5
2022
Statut:
epublish
Résumé
The occurrence of cancer in newborns within the first 28 days of life is uncommon, with different clinical presentation from other age groups. Prenatal diagnosis is reported in about half of patients, while a genetic predisposition condition is supposed. The management of a newborn with cancer can be challenging and needs to be tailored according to the histology and the primary tumor site; surgery represents the main strategy, while chemotherapy should be considered with caution because of the higher toxicity and mortality due to different pharmacokinetics in neonates compared to older children. We describe the first Italian series over a 15-year period of patients affected by both benign and malignant neoplastic diseases diagnosed within the first 28 days of life; 74 newborns were diagnosed with neonatal tumors, representing 1.5% of the cancer population in the same period, and a prevalence of germ cell tumors (55%) and neuroblastoma (16%) was observed. Surgery was performed on 80% of patients, while chemotherapy was necessary for about 20% of patients. The 5-year overall survival (OS) exceeded 90%; treatment-related deaths are a major concern, representing 80% of overall deaths. A genetic/syndromic condition was detected in 16% of the population; additionally, a cancer predisposition syndrome (CPS) was identified in about 10% of patients. According to our experience, all newborns affected by cancer should warrant genetic counselling and a screening test for CPS.
Identifiants
pubmed: 35565372
pii: cancers14092244
doi: 10.3390/cancers14092244
pmc: PMC9103742
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Front Pediatr. 2021 Mar 08;9:661894
pubmed: 33763398
Lancet Oncol. 2013 Dec;14(13):e609-20
pubmed: 24275134
Cancer Med. 2017 Jul;6(7):1817-1826
pubmed: 28639735
Semin Fetal Neonatal Med. 2012 Aug;17(4):183-184
pubmed: 22572199
Cancer. 2001 Sep 15;92(6):1613-20
pubmed: 11745240
Genet Med. 2021 Jul;23(7):1366-1371
pubmed: 33767345
Lancet. 2017 Oct 14;390(10104):1770-1780
pubmed: 28434651
J Pediatr Hematol Oncol. 2020 Jul;42(5):e286-e292
pubmed: 31815889
Pediatr Neonatol. 2018 Feb;59(1):65-70
pubmed: 28736178
BMC Pediatr. 2018 May 15;18(1):166
pubmed: 29764408
Cancer. 2002 May 1;94(9):2474-80
pubmed: 12015773
Semin Fetal Neonatal Med. 2012 Aug;17(4):243-248
pubmed: 22464845
Diagnostics (Basel). 2020 Aug 28;10(9):
pubmed: 32872331
Pediatr Surg Int. 2003 Sep;19(7):509-19
pubmed: 14523568
J Pediatr Surg. 2011 Jul;46(7):1325-32
pubmed: 21763829
Pediatr Blood Cancer. 2016 Aug;63(8):1375-80
pubmed: 27093073
Clin Perinatol. 2021 Mar;48(1):1-14
pubmed: 33583498
N Engl J Med. 2003 Sep 18;349(12):1157-67
pubmed: 13679531
Cancer Chemother Pharmacol. 2010 May;65(6):1057-66
pubmed: 19701749
Lancet. 2012 Aug 4;380(9840):499-505
pubmed: 22681860
Cancer Discov. 2020 Jul;10(7):942-963
pubmed: 32238360
Front Oncol. 2021 Dec 13;11:794498
pubmed: 34966688
Semin Fetal Neonatal Med. 2012 Aug;17(4):231-238
pubmed: 22633289
Acta Neuropathol. 2016 Jun;131(6):803-20
pubmed: 27157931
Int J Cancer. 2006 Nov 1;119(9):2001-6
pubmed: 16642469